Zantac Recall

Zantac Recall

ZANTAC RECALLED DUE TO POTENTIAL CANCER RISK

On April 1, 2019, the Food and Drug Administration (FDA) recalled all prescription and over-the-counter Zantac (Ranitidine) drugs from the market. This was the latest step in a long running investigation related to contaminated Zantac. The FDA determined that the contaminate known as N-Nitrosodimethylamine (NDMA) increased over time and when stored at room temperatures may expose consumers to unacceptable levels of NDMA.

NDMA is a known human carcinogen – meaning is could cause cancer. Lawsuits claim that Zantac cause the following types of cancer:

Bladder Cancer
Colorectal Cancer
Esophageal Cancer
Intestinal Cancer
Kidney Cancer
Liver Cancer
Pancreatic Cancer
Stomach Cancer
Testicular Cancer
Uterine or Ovarian Cancer

Yaeger Law is investigating cases in which patients took Zantac or generic forms of Rantidine and then developed certain cancers. If you or a loved one experienced injuries related to Zantac, you may be entitled to compensation. Contact Yaeger Law to discuss the details of your potential Zantac Lawsuit.

TIMELINE OF RECALLS:

11/19/2019: Precision Dose recalls ranitidine oral solution, USP 150 mg/10 ml due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.

11/15/2019: Golden State Medical Supply (GSMS, Inc.) recalls ranitidine HCl 150mg and 300mg capsules due to potential presence of n-nitrosodimethylamine (NDMA) above levels established by the FDA.

11/8/2019: Amneal Pharmaceuticals recalls ranitidine tablets, 150 mg and 300 mg, and ranitidine syrup (ranitidine oral solution, USP), 15 mg/ml due to due to potential n-nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

11/8/2019: American Health Packaging recalls ranitidine liquid unit dose cups due to NDMA impurity.

11/6/2019: Aurobindo & DG Health recalls ranitidine due to NDMA impurity.

10/25/2019: Novitium Pharma recalls ranitidine hydrochloride capsules 150 mg and 300 mg because it may contain n-nitrosodimethylamine (NDMA).

10/25/2019: Lannett Company, Inc. recalls ranitidine syrup (ranitidine oral solution, USP), 15mg/ml due to above levels of NDMA.

10/23/2019: Dr. Reddy’s, Kroger, Walgreens, and others recall ranitidine tablets & capsules for containing N-Nitrosodimethylamine (NDMA).

10/23/2019: Perrigo Company plc recalls Ranitidine (all pack sizes) for the presence of N-Nitrosodimethylamine (NDMA).

10/22/2019: Sanofi recalls all Zantac OTC products in the U.S. for possibly containing N-Nitrosodimethylamine (NDMA).

9/25/2019: Apotex Corp. recalls 75mg and 150mg ranitidine tablets for containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA)

9/23/2019: Sandoz Inc. recalled ranitidine hydrochloride capsules due to an elevated amount of an unexpected impurity, N-nitrosodimethylamine (NDMA)

contact us for a free consultation